The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...
Three U.S. senators are calling on Robert Kennedy Jr. to disclose what he and President Trump discussed with drugmakers ...
Over the weekend, the federal government eliminated thousands of employees from health care agencies in key jobs, such as the FDA’s head of medical device safety. Because AI is so new ...
The FDA's announcement comes months after drugmaker Novo Nordisk told the agency that all dosages of its semaglutide product had become fully available nationwide. The company said in a statement ...
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. Fellow Japanese drugmaker Ono Pharmaceutical has won an FDA green light for vimseltinib to treat ...
In a statement, the FDA said it confirmed Novo Nordisk's "stated product availability and manufacturing capacity" of these prescription drugs meets or exceeds current and projected demand.
The Food and Drug Administration (FDA) raised the risk level of the recall ... product to the store where they bought it for a full refund.” The recall affects products with various UPC ...
FDA reviewers of Elon Musk's Neuralink among those fired Current and former FDA officials are worried about safety of trials for Neuralink, other medical devices Feb 17 (Reuters) - U.S. Food and ...
“The delay should not alter the impact, as full compliance is still years away,” he said. “This is a big win for consumers. The FDA is finally identifying healthy foods based on nourishing ...
The update about the popular semaglutide injections from drug manufacturer Novo Nordisk follows just two months after the FDA said that shortages of tirzepatide injections Zepbound and Mounjaro ...
Bates found that the challengers were likely to succeed in their claims that the Department Health and Human Services, CDC and FDA acted unlawfully when they stripped medical information from ...
A little less than two years after San Francisco’s Mirum Pharmaceuticals ponied up $210 million to acquire Travere Therapeutics’ bile acid portfolio, the deal has paid off with a fresh FDA ...